Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
Top Cited Papers
- 1 September 2010
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 182 (5), 627-632
- https://doi.org/10.1164/rccm.200909-1421oc
Abstract
Patients with cystic fibrosis periodically experience pulmonary exacerbations. Previous studies have noted that some patients' lung function (FEV(1)) does not improve with treatment. To determine the proportion of patients treated for a pulmonary exacerbation that does not recover to spirometric baseline, and to identify factors associated with the failure to recover to spirometric baseline. Cohort study using the Cystic Fibrosis Foundation Patient Registry from 2003-2006. We randomly selected one pulmonary exacerbation treated with intravenous antibiotics per patient and compared the best FEV(1) in the 3 months after treatment with the best FEV(1) in the 6 months before treatment. Recovery to baseline was defined as any FEV(1) in the 3 months after treatment that was greater than or equal to 90% of the baseline FEV(1). Multivariable logistic regression was used to estimate associations with the failure to recover to baseline FEV(1). Of 8,479 pulmonary exacerbations, 25% failed to recover to baseline FEV(1). A higher risk of failing to recover to baseline was associated with female sex; pancreatic insufficiency; being undernourished; Medicaid insurance; persistent infection with Pseudomonas aeruginosa, Burkholderia cepacia complex, or methicillin-resistant Staphylococcus aureus; allergic bronchopulmonary aspergillosis; a longer time since baseline spirometric assessment; and a larger drop in FEV(1) from baseline to treatment initiation. For a randomly selected pulmonary exacerbation, 25% of patients' pulmonary function did not recover to baseline after treatment with intravenous antibiotics. We identified factors associated with the failure to recover to baseline, allowing clinicians to identify patients who may benefit from closer monitoring and more aggressive treatment.This publication has 30 references indexed in Scilit:
- Return of FEV1 after pulmonary exacerbation in children with cystic fibrosisPediatric Pulmonology, 2010
- Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosaPediatric Pulmonology, 2009
- Predictors of mortality in adults with cystic fibrosisPediatric Pulmonology, 2007
- Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesisThorax, 2007
- Interpretative strategies for lung function testsEuropean Respiratory Journal, 2005
- Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosisPediatric Pulmonology, 2003
- Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosisThe Journal of Pediatrics, 1999
- Management of Pulmonary Disease in Patients with Cystic FibrosisThe New England Journal of Medicine, 1996
- Evolution of pulmonary function during an acute exacerbation in hospitalized patients with cystic fibrosisPediatric Pulmonology, 1993
- Pulmonary function between 6 and 18 years of agePediatric Pulmonology, 1993